PrEP at a Syringe Services Program

University of Miami

Status and phase: Completed; Phase 4

Conditions: Substance Use Disorders; Hiv

Treatments: Behavioral: PrEP; Drug: Descovy 200Mg 25Mg Tablet

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04782180

20210017

Details and patient eligibility

About

The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.

Enrollment: 90 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. over the age of 18
2. speak either English or Spanish
3. ability to provide informed consent
4. currently enrolled in the syringe services program
5. have a negative HIV rapid test result
6. estimated creatinine clearance > 30 ml/minute

Exclusion criteria

1. do not meet the above criteria of inclusion
2. decline to participate
3. test positive for HIV via rapid test
4. are pregnant or plan on becoming pregnant
5. have symptoms acute HIV.
6. Any other comorbidities that at the discretion of the investigator would prevent the participant from participating in the study.

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

90 participants in 1 patient group

Rapid PrEP group

Experimental group

Description:

Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.

Treatment:

Drug: Descovy 200Mg 25Mg Tablet

Behavioral: PrEP